Latest news with #MedicalServices
Time of India
10-08-2025
- Health
- Time of India
Delhi: Adult vaccination centre and Bronchoscopy suite inaugurated at Army hospital (R&R)
New Delhi: Director General Medical Services (Army) and Senior Colonel Commandant Lt Gen Sadhna S Nair inaugurated the Adult Vaccination Centre and a state-of-the-art Bronchoscopy Suite at the Army Hospital Research and Referral, New Delhi on Saturday. Defence Ministry said that the Centre will provide comprehensive immunisation services to all eligible adults, offering vaccines for Influenza, Pneumococcus, Hepatitis, and other preventable diseases. The newly established Bronchoscopy Suite is equipped with advanced technology for performing a wide range of diagnostic and therapeutic airway procedures. The facilities aim to enhance preventive healthcare and advanced diagnostic capabilities for patients visiting the hospital. The inauguration ceremony was attended by Commandant Lt Gen Shankar Narayan; Deputy Commandant Maj Gen Amul Kapoor, along with senior officers from the hospital, station, and the Directorate. (ANI)
Yahoo
08-08-2025
- Business
- Yahoo
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Misses Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -5.56%. A quarter ago, it was expected that this company would post a loss of $0.83 per share when it actually produced a loss of $0.7, delivering a surprise of +15.66%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Establishment Labs, which belongs to the Zacks Medical Services industry, posted revenues of $51.3 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.59%. This compares to year-ago revenues of $44.12 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Establishment Labs shares have lost about 9.3% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for Establishment Labs? While Establishment Labs has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Establishment Labs was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.43 on $52.55 million in revenues for the coming quarter and -$1.99 on $207.13 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Sotera Health Company (SHC), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 8. This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of -10.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Sotera Health Company's revenues are expected to be $276.08 million, down 0.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Establishment Labs Holdings Inc. (ESTA) : Free Stock Analysis Report Sotera Health Company (SHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
08-08-2025
- Business
- Yahoo
Solventum (SOLV) Beats Q2 Earnings and Revenue Estimates
Solventum (SOLV) came out with quarterly earnings of $1.69 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +16.55%. A quarter ago, it was expected that this health care company would post earnings of $1.19 per share when it actually produced earnings of $1.34, delivering a surprise of +12.61%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Solventum, which belongs to the Zacks Medical Services industry, posted revenues of $2.16 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.87%. This compares to year-ago revenues of $2.08 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Solventum shares have added about 9.9% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for Solventum? While Solventum has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Solventum was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.37 on $2.11 billion in revenues for the coming quarter and $5.58 on $8.43 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. PACS Group, Inc. (PACS), another stock in the same industry, has yet to report results for the quarter ended June 2025. This company is expected to post quarterly earnings of $0.47 per share in its upcoming report, which represents a year-over-year change of +771.4%. The consensus EPS estimate for the quarter has been revised 2.2% higher over the last 30 days to the current level. PACS Group, Inc.'s revenues are expected to be $1.11 billion, up 12.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Solventum Corporation (SOLV) : Free Stock Analysis Report PACS Group, Inc. (PACS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Hans India
01-08-2025
- Health
- Hans India
Army's top med services official visits Military Hosp in Sec'bad
Hyderabad: On July 30, 2025, Lieutenant General Sadhna S Nair, AVSM, VSM, the Director General of Medical Services (Army) and Senior Colonel Commandant of the Army Medical Corps, conducted a comprehensive visit to the Military Hospital in Secunderabad. This visit reaffirmed her commitment to advancing operational excellence and innovation in military healthcare. Brigadier Vishal Vir Sharma, SM, Commandant of the hospital, welcomed the General Officer and provided detailed briefings on clinical services, strategic readiness, infrastructure capabilities, and the hospital's vital role in the Dakshin Bharat Area. Lieutenant General Nair began her inspection at the Cath Lab, where she observed advanced cardiac interventions and emergency preparedness protocols. She commended the clinical team for maintaining exemplary standards and for their swift response mechanisms in high-risk situations. At the MRI Centre, she reviewed the deployment of high-resolution imaging systems that enhance cross-disciplinary diagnostic accuracy. These improved capabilities were recognised as crucial for effectively managing complex clinical scenarios. During her tour of the Birthing Centre, she engaged with medical personnel about integrating patient-friendly facilities and reinforced the importance of obstetric support. She praised the upgraded neonatal monitoring and postnatal care, highlighting their positive impact on health outcomes. The DGMS evaluated the newly operational Laboratory Information System (LIS), which streamlines diagnostics, reduces processing delays, and minimises errors. She emphasised how this system enhances clinical decision-making and service delivery. Lieutenant General Nair also held interactive sessions with medical and support staff to encourage continuous feedback, collaboration, and innovation. She acknowledged the hospital's resilience and adaptability in the face of increasing healthcare demands. After touring the Military Hospital, the General Officer proceeded to the 454 Field Hospital, where she received briefings from the Commanding Officers of both the 354 and 454 Field Hospitals. Discussions centred around operational readiness, deployment logistics, and medical support in dynamic field environments. Lieutenant General Sadhna S Nair praised the dedication of all personnel within Army Medical Corps establishments, encouraging a sustained focus on patient-centric care, technological integration, and mission-driven service excellence.
Zawya
31-07-2025
- Business
- Zawya
Saudi: Mouwasat logs over $102mln profits in H1-25
Riyadh: Mouwasat Medical Services Company posted 18.41% year-on-year (YoY) higher net profits at SAR 384.01 million in the first half (H1) of 2025, versus SAR 324.28 million. The revenues increased by 10.44% to SAR 1.56 billion in H1-25 from SAR 1.41 billion a year earlier, according to the financial statements. Earnings per share (EPS) hit SAR 1.92 as of 30 June 2025, higher than SAR 1.62 in H1-24. Financials for Q2-25 In the second quarter (Q2) of 2025, Mouwasat achieved net profits valued at SAR 186.97 million, an annual hike of 22.44% from SAR 152.70 million. Revenues amounted to SAR 796.35 million in the April-June 2025 period, up 15.36% YoY from SAR 690.30 million. Quarterly, the Q2-25 net profits dropped by 5.11% from SAR 197.05 million in Q1-25, while the revenues jumped by 4.18% from SAR 764.35 million. All Rights Reserved - Mubasher Info © 2005 - 2025 Provided by SyndiGate Media Inc. (
